Tags

Type your tag names separated by a space and hit enter

Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Eur J Haematol. 2008 Jan; 80(1):46-54.EJ

Abstract

OBJECTIVES

Circulating gelatinases and their tissue inhibitors measured at diagnosis have been shown to exhibit prognostic relevance in several solid tumours. The clinical data concerning their role in follow-up of cancer are still very preliminary. The aim of this study was to find out whether the concentrations of these circulating markers could be used as follow-up markers predicting the risk of lymphoma relapse.

METHODS

Here, we investigated these circulating molecules in a large (n = 126) follow-up material of lymphoma patients and in healthy controls (n = 44). The plasma samples of patients with Hodgkin's lymphoma (n = 31), non-Hodgkin's lymphoma (n = 95), and healthy controls were analysed by enzyme-linked immunosorbent assay for matrix metalloproteinase-9 (MMP-9), proMMP-2, matrix metalloproteinase-2-tissue inhibitor of metalloproteinase-2 (MMP-2-TIMP-2) complex, TIMP-1, and TIMP-2.

RESULTS

The patients with the highest plasma levels of MMP-2-TIMP-2 complex had a 3-fold risk of relapse when compared to the patients with lower levels (P = 0.036). Plasma levels of proMMP-2 and MMP-2-TIMP-2 complex as well as the proMMP-2/TIMP-2 ratio were significantly higher in patients with active lymphoma and those in remission when compared to healthy controls. On the contrary, the values of TIMP-2 were significantly lower in lymphoma patients than in controls.

CONCLUSIONS

This study shows that lymphoma patients with the highest levels of MMP-2-TIMP-2 complex are at a marked risk of relapse. Moreover, plasma levels of MMP-2-TIMP-2 complex, proMMP-2, TIMP-2, and proMMP-2/TIMP-2 ratio are at abnormal level in patients with newly diagnosed lymphoma and those in remission when compared to healthy controls. They remain abnormal even after successful lymphoma treatments.

Authors+Show Affiliations

Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland. heli@kyllonen.fiNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18028436

Citation

Pennanen, Heli, et al. "Plasma MMP-2-TIMP-2 Complex Levels Measured During Follow-up Predict a Risk of Relapse in Patients With Malignant Lymphoma." European Journal of Haematology, vol. 80, no. 1, 2008, pp. 46-54.
Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. Eur J Haematol. 2008;80(1):46-54.
Pennanen, H., Kuittinen, O., & Turpeenniemi-Hujanen, T. (2008). Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. European Journal of Haematology, 80(1), 46-54.
Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 Complex Levels Measured During Follow-up Predict a Risk of Relapse in Patients With Malignant Lymphoma. Eur J Haematol. 2008;80(1):46-54. PubMed PMID: 18028436.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. AU - Pennanen,Heli, AU - Kuittinen,Outi, AU - Turpeenniemi-Hujanen,Taina, Y1 - 2007/11/19/ PY - 2007/11/22/pubmed PY - 2008/1/31/medline PY - 2007/11/22/entrez SP - 46 EP - 54 JF - European journal of haematology JO - Eur J Haematol VL - 80 IS - 1 N2 - OBJECTIVES: Circulating gelatinases and their tissue inhibitors measured at diagnosis have been shown to exhibit prognostic relevance in several solid tumours. The clinical data concerning their role in follow-up of cancer are still very preliminary. The aim of this study was to find out whether the concentrations of these circulating markers could be used as follow-up markers predicting the risk of lymphoma relapse. METHODS: Here, we investigated these circulating molecules in a large (n = 126) follow-up material of lymphoma patients and in healthy controls (n = 44). The plasma samples of patients with Hodgkin's lymphoma (n = 31), non-Hodgkin's lymphoma (n = 95), and healthy controls were analysed by enzyme-linked immunosorbent assay for matrix metalloproteinase-9 (MMP-9), proMMP-2, matrix metalloproteinase-2-tissue inhibitor of metalloproteinase-2 (MMP-2-TIMP-2) complex, TIMP-1, and TIMP-2. RESULTS: The patients with the highest plasma levels of MMP-2-TIMP-2 complex had a 3-fold risk of relapse when compared to the patients with lower levels (P = 0.036). Plasma levels of proMMP-2 and MMP-2-TIMP-2 complex as well as the proMMP-2/TIMP-2 ratio were significantly higher in patients with active lymphoma and those in remission when compared to healthy controls. On the contrary, the values of TIMP-2 were significantly lower in lymphoma patients than in controls. CONCLUSIONS: This study shows that lymphoma patients with the highest levels of MMP-2-TIMP-2 complex are at a marked risk of relapse. Moreover, plasma levels of MMP-2-TIMP-2 complex, proMMP-2, TIMP-2, and proMMP-2/TIMP-2 ratio are at abnormal level in patients with newly diagnosed lymphoma and those in remission when compared to healthy controls. They remain abnormal even after successful lymphoma treatments. SN - 1600-0609 UR - https://www.unboundmedicine.com/medline/citation/18028436/Plasma_MMP_2_TIMP_2_complex_levels_measured_during_follow_up_predict_a_risk_of_relapse_in_patients_with_malignant_lymphoma_ L2 - https://doi.org/10.1111/j.1600-0609.2007.00975.x DB - PRIME DP - Unbound Medicine ER -